Dr. Samuel J. Kerr
Claim this profilePenn Medicine Lancaster General Health
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
3 reported clinical trials
10 drugs studied
Area of expertise
1Lung Cancer
Stage IV
Stage II
Stage I
2Non-Small Cell Lung Cancer
Stage IV
MET positive
KRAS positive
Affiliated Hospitals
Clinical Trials Samuel J. Kerr is currently running
Liquid Biopsy NGS Prompt
for Lung Cancer
This study expands the application of an electronic health record (EHR) "nudge" used to prompt physicians' clinical practice to order molecular testing at the time of initial diagnosis for patients with specific types of advanced lung cancer. The primary goal is to have these test results available prior to starting treatment so that physicians can make molecularly-informed treatment decisions. The second goal is to better understand factors that contribute to whether or not the EHR-nudge implementation is successful.
Recruiting1 award N/A2 criteria
Ramucirumab + Pembrolizumab vs Chemotherapy
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out if giving ramucirumab with pembrolizumab is more effective at treating patients with stage IV or recurrent non-small cell lung cancer than standard chemotherapy.
Recruiting2 awards Phase 310 criteria
More about Samuel J. Kerr
Clinical Trial Related5 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Samuel J. Kerr has experience with
- INUDGE
- Atezolizumab
- Cisplatin
- Carboplatin
- Etoposide
- 3-Dimensional Conformal Radiation Therapy
Breakdown of trials Samuel J. Kerr has run
Lung Cancer
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Small Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Samuel J. Kerr specialize in?
Samuel J. Kerr focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage II.
Is Samuel J. Kerr currently recruiting for clinical trials?
Yes, Samuel J. Kerr is currently recruiting for 2 clinical trials in Lancaster Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Samuel J. Kerr has studied deeply?
Yes, Samuel J. Kerr has studied treatments such as iNUDGE, Atezolizumab, Cisplatin.
What is the best way to schedule an appointment with Samuel J. Kerr?
Apply for one of the trials that Samuel J. Kerr is conducting.
What is the office address of Samuel J. Kerr?
The office of Samuel J. Kerr is located at: Penn Medicine Lancaster General Health, Lancaster, Pennsylvania 17602 United States. This is the address for their practice at the Penn Medicine Lancaster General Health.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.